Rallybio (RLYB) said Tuesday it will discontinue development of RLYB212 after the drug failed to reach expected concentration levels in a phase 2 trial.
The company said that RLYB212 did not meet the predicted or minimum drug concentration needed for effectiveness in its phase 2 study for the prevention of fetal and neonatal alloimmune thrombocytopenia, a rare immune disorder.
Rallybio said no further enrollment will occur, and the program will be discontinued.
Rallybio said it will now focus on RLYB116, with a confirmatory pharmacokinetic/pharmacodynamic study set to begin in Q2. Data from the first two cohorts is expected in H2, the company said.
Rallybio shares fell by more than 32% in early trading on Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.